Global Anthrax Vaccines Sales 麻豆原创 Report 2023

Publication ID:

PB501238816

Publication Date:

January 4, 2023

Pages:

152

Publisher:

MRRPB5

Countries:

Global [1]

USD 4,000.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Anthrax is a serious disease that can affect both animals and humans. It is caused by bacteria called Bacillus anthracis. People can get anthrax from contact with infected animals, wool, meat, or hides.Anthrax vaccine protects against anthrax disease. Anthrax vaccine was licensed in 1970.Based on limited but sound evidence, the vaccine protects against both cutaneous (skin) and inhalation anthrax.
麻豆原创 Analysis and Insights: Global Anthrax Vaccines 麻豆原创
Due to the COVID-19 pandemic, the global Anthrax Vaccines market size is estimated to be worth US$ 655 million in 2022 and is forecast to a readjusted size of US$ 1100.3 million by 2029 with a CAGR of 7.6% during the forecast period 2023-2029. Fully considering the economic change by this health crisis, Live Vaccines accounting for % of the Anthrax Vaccines global market in 2022, is projected to value US$ million by 2029, growing at a revised % CAGR from 2023 to 2029. While Human Use segment is altered to an % CAGR throughout this forecast period.
Global Anthrax Vaccines key players include Emergent BioSolutions, Merial, Merck, Zoetis, PharmAthene, etc. Global top five players hold a share about 70%.
North America is the largest market, with a share about 60%, followed by Latin America and Europe, having a total share about 20 percent.
In terms of product, Live Vaccines is the largest segment, with a share about 95%. And in terms of application, the largest application is Human Use, followed by Animal Use.
Global Anthrax Vaccines Scope and 麻豆原创 Size
The global Anthrax Vaccines market is segmented by company, region (country), type and application. Players, stakeholders, and other participants in the global Anthrax Vaccines market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), type and application for the period 2018-2029.
Segment by Type
Live Vaccines
Cell free PA Vaccines
Segment by Application
Human Use
Animal Use
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
By Company
Emergent BioSolutions
Merial
Merck
Zoetis
Bayer Sanidad Animal
Colorado Serum
PharmAthene
Tiankang
叠颈辞驳茅苍别蝉颈蝉-叠补驳辞
CAVAC
Rosenbusch
Agrovet
Vecol
CVCRI
IVPM
Prondil
CDV
Indian Immunologicals
Botswana Vaccine Institute
Ceva Sant茅 Animale
Intervac
JOVAC

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Anthrax Vaccines 麻豆原创 Overview
1.1 Anthrax Vaccines Product Scope
1.2 Anthrax Vaccines Segment by Type
1.2.1 Global Anthrax Vaccines Sales by Type (2018 & 2022 & 2029)
1.2.2 Live Vaccines
1.2.3 Cell free PA Vaccines
1.3 Anthrax Vaccines Segment by Application
1.3.1 Global Anthrax Vaccines Sales Comparison by Application (2018 & 2022 & 2029)
1.3.2 Human Use
1.3.3 Animal Use
1.4 Anthrax Vaccines 麻豆原创 Estimates and Forecasts (2018-2029)
1.4.1 Global Anthrax Vaccines 麻豆原创 Size in Value Growth Rate (2018-2029)
1.4.2 Global Anthrax Vaccines 麻豆原创 Size in Volume Growth Rate (2018-2029)
1.4.3 Global Anthrax Vaccines Price Trends (2018-2029)
2 Anthrax Vaccines Estimates and Forecasts by Region
2.1 Global Anthrax Vaccines 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2 Global Anthrax Vaccines Retrospective 麻豆原创 Scenario by Region (2018-2023)
2.2.1 Global Anthrax Vaccines Sales 麻豆原创 Share by Region (2018-2023)
2.2.2 Global Anthrax Vaccines Revenue 麻豆原创 Share by Region (2018-2023)
2.3 Global Anthrax Vaccines 麻豆原创 Estimates and Forecasts by Region (2024-2029)
2.3.1 Global Anthrax Vaccines Sales Estimates and Forecasts by Region (2024-2029)
2.3.2 Global Anthrax Vaccines Revenue Forecast by Region (2024-2029)
2.4 Geographic 麻豆原创 Analysis: 麻豆原创 Facts & Figures
2.4.1 United States Anthrax Vaccines Estimates and Projections (2018-2029)
2.4.2 Europe Anthrax Vaccines Estimates and Projections (2018-2029)
2.4.3 China Anthrax Vaccines Estimates and Projections (2018-2029)
2.4.4 Japan Anthrax Vaccines Estimates and Projections (2018-2029)
2.4.5 Southeast Asia Anthrax Vaccines Estimates and Projections (2018-2029)
2.4.6 India Anthrax Vaccines Estimates and Projections (2018-2029)
3 Global Anthrax Vaccines Competition Landscape by Players
3.1 Global Top Anthrax Vaccines Players by Sales (2018-2023)
3.2 Global Top Anthrax Vaccines Players by Revenue (2018-2023)
3.3 Global Anthrax Vaccines 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Anthrax Vaccines as of 2022)
3.4 Global Anthrax Vaccines Average Price by Company (2018-2023)
3.5 Manufacturers Anthrax Vaccines Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Global Anthrax Vaccines 麻豆原创 Size by Type
4.1 Global Anthrax Vaccines Historic 麻豆原创 Review by Type (2018-2023)
4.1.1 Global Anthrax Vaccines Sales by Type (2018-2023)
4.1.2 Global Anthrax Vaccines Revenue by Type (2018-2023)
4.1.3 Global Anthrax Vaccines Price by Type (2018-2023)
4.2 Global Anthrax Vaccines 麻豆原创 Estimates and Forecasts by Type (2024-2029)
4.2.1 Global Anthrax Vaccines Sales Forecast by Type (2024-2029)
4.2.2 Global Anthrax Vaccines Revenue Forecast by Type (2024-2029)
4.2.3 Global Anthrax Vaccines Price Forecast by Type (2024-2029)
5 Global Anthrax Vaccines 麻豆原创 Size by Application
5.1 Global Anthrax Vaccines Historic 麻豆原创 Review by Application (2018-2023)
5.1.1 Global Anthrax Vaccines Sales by Application (2018-2023)
5.1.2 Global Anthrax Vaccines Revenue by Application (2018-2023)
5.1.3 Global Anthrax Vaccines Price by Application (2018-2023)
5.2 Global Anthrax Vaccines 麻豆原创 Estimates and Forecasts by Application (2024-2029)
5.2.1 Global Anthrax Vaccines Sales Forecast by Application (2024-2029)
5.2.2 Global Anthrax Vaccines Revenue Forecast by Application (2024-2029)
5.2.3 Global Anthrax Vaccines Price Forecast by Application (2024-2029)
6 United States Anthrax Vaccines 麻豆原创 Facts & Figures
6.1 United States Anthrax Vaccines Sales by Company
6.1.1 United States Anthrax Vaccines Sales by Company (2018-2023)
6.1.2 United States Anthrax Vaccines Revenue by Company (2018-2023)
6.2 United States Anthrax Vaccines Sales Breakdown by Type
6.2.1 United States Anthrax Vaccines Sales Breakdown by Type (2018-2023)
6.2.2 United States Anthrax Vaccines Sales Breakdown by Type (2024-2029)
6.3 United States Anthrax Vaccines Sales Breakdown by Application
6.3.1 United States Anthrax Vaccines Sales Breakdown by Application (2018-2023)
6.3.2 United States Anthrax Vaccines Sales Breakdown by Application (2024-2029)
7 Europe Anthrax Vaccines 麻豆原创 Facts & Figures
7.1 Europe Anthrax Vaccines Sales by Company
7.1.1 Europe Anthrax Vaccines Sales by Company (2018-2023)
7.1.2 Europe Anthrax Vaccines Revenue by Company (2018-2023)
7.2 Europe Anthrax Vaccines Sales Breakdown by Type
7.2.1 Europe Anthrax Vaccines Sales Breakdown by Type (2018-2023)
7.2.2 Europe Anthrax Vaccines Sales Breakdown by Type (2024-2029)
7.3 Europe Anthrax Vaccines Sales Breakdown by Application
7.3.1 Europe Anthrax Vaccines Sales Breakdown by Application (2018-2023)
7.3.2 Europe Anthrax Vaccines Sales Breakdown by Application (2024-2029)
8 China Anthrax Vaccines 麻豆原创 Facts & Figures
8.1 China Anthrax Vaccines Sales by Company
8.1.1 China Anthrax Vaccines Sales by Company (2018-2023)
8.1.2 China Anthrax Vaccines Revenue by Company (2018-2023)
8.2 China Anthrax Vaccines Sales Breakdown by Type
8.2.1 China Anthrax Vaccines Sales Breakdown by Type (2018-2023)
8.2.2 China Anthrax Vaccines Sales Breakdown by Type (2024-2029)
8.3 China Anthrax Vaccines Sales Breakdown by Application
8.3.1 China Anthrax Vaccines Sales Breakdown by Application (2018-2023)
8.3.2 China Anthrax Vaccines Sales Breakdown by Application (2024-2029)
9 Japan Anthrax Vaccines 麻豆原创 Facts & Figures
9.1 Japan Anthrax Vaccines Sales by Company
9.1.1 Japan Anthrax Vaccines Sales by Company (2018-2023)
9.1.2 Japan Anthrax Vaccines Revenue by Company (2018-2023)
9.2 Japan Anthrax Vaccines Sales Breakdown by Type
9.2.1 Japan Anthrax Vaccines Sales Breakdown by Type (2018-2023)
9.2.2 Japan Anthrax Vaccines Sales Breakdown by Type (2024-2029)
9.3 Japan Anthrax Vaccines Sales Breakdown by Application
9.3.1 Japan Anthrax Vaccines Sales Breakdown by Application (2018-2023)
9.3.2 Japan Anthrax Vaccines Sales Breakdown by Application (2024-2029)
10 Southeast Asia Anthrax Vaccines 麻豆原创 Facts & Figures
10.1 Southeast Asia Anthrax Vaccines Sales by Company
10.1.1 Southeast Asia Anthrax Vaccines Sales by Company (2018-2023)
10.1.2 Southeast Asia Anthrax Vaccines Revenue by Company (2018-2023)
10.2 Southeast Asia Anthrax Vaccines Sales Breakdown by Type
10.2.1 Southeast Asia Anthrax Vaccines Sales Breakdown by Type (2018-2023)
10.2.2 Southeast Asia Anthrax Vaccines Sales Breakdown by Type (2024-2029)
10.3 Southeast Asia Anthrax Vaccines Sales Breakdown by Application
10.3.1 Southeast Asia Anthrax Vaccines Sales Breakdown by Application (2018-2023)
10.3.2 Southeast Asia Anthrax Vaccines Sales Breakdown by Application (2024-2029)
11 India Anthrax Vaccines 麻豆原创 Facts & Figures
11.1 India Anthrax Vaccines Sales by Company
11.1.1 India Anthrax Vaccines Sales by Company (2018-2023)
11.1.2 India Anthrax Vaccines Revenue by Company (2018-2023)
11.2 India Anthrax Vaccines Sales Breakdown by Type
11.2.1 India Anthrax Vaccines Sales Breakdown by Type (2018-2023)
11.2.2 India Anthrax Vaccines Sales Breakdown by Type (2024-2029)
11.3 India Anthrax Vaccines Sales Breakdown by Application
11.3.1 India Anthrax Vaccines Sales Breakdown by Application (2018-2023)
11.3.2 India Anthrax Vaccines Sales Breakdown by Application (2024-2029)
12 Company Profiles and Key Figures in Anthrax Vaccines Business
12.1 Emergent BioSolutions
12.1.1 Emergent BioSolutions Corporation Information
12.1.2 Emergent BioSolutions Business Overview
12.1.3 Emergent BioSolutions Anthrax Vaccines Sales, Revenue and Gross Margin (2018-2023)
12.1.4 Emergent BioSolutions Anthrax Vaccines Products Offered
12.1.5 Emergent BioSolutions Recent Development
12.2 Merial
12.2.1 Merial Corporation Information
12.2.2 Merial Business Overview
12.2.3 Merial Anthrax Vaccines Sales, Revenue and Gross Margin (2018-2023)
12.2.4 Merial Anthrax Vaccines Products Offered
12.2.5 Merial Recent Development
12.3 Merck
12.3.1 Merck Corporation Information
12.3.2 Merck Business Overview
12.3.3 Merck Anthrax Vaccines Sales, Revenue and Gross Margin (2018-2023)
12.3.4 Merck Anthrax Vaccines Products Offered
12.3.5 Merck Recent Development
12.4 Zoetis
12.4.1 Zoetis Corporation Information
12.4.2 Zoetis Business Overview
12.4.3 Zoetis Anthrax Vaccines Sales, Revenue and Gross Margin (2018-2023)
12.4.4 Zoetis Anthrax Vaccines Products Offered
12.4.5 Zoetis Recent Development
12.5 Bayer Sanidad Animal
12.5.1 Bayer Sanidad Animal Corporation Information
12.5.2 Bayer Sanidad Animal Business Overview
12.5.3 Bayer Sanidad Animal Anthrax Vaccines Sales, Revenue and Gross Margin (2018-2023)
12.5.4 Bayer Sanidad Animal Anthrax Vaccines Products Offered
12.5.5 Bayer Sanidad Animal Recent Development
12.6 Colorado Serum
12.6.1 Colorado Serum Corporation Information
12.6.2 Colorado Serum Business Overview
12.6.3 Colorado Serum Anthrax Vaccines Sales, Revenue and Gross Margin (2018-2023)
12.6.4 Colorado Serum Anthrax Vaccines Products Offered
12.6.5 Colorado Serum Recent Development
12.7 PharmAthene
12.7.1 PharmAthene Corporation Information
12.7.2 PharmAthene Business Overview
12.7.3 PharmAthene Anthrax Vaccines Sales, Revenue and Gross Margin (2018-2023)
12.7.4 PharmAthene Anthrax Vaccines Products Offered
12.7.5 PharmAthene Recent Development
12.8 Tiankang
12.8.1 Tiankang Corporation Information
12.8.2 Tiankang Business Overview
12.8.3 Tiankang Anthrax Vaccines Sales, Revenue and Gross Margin (2018-2023)
12.8.4 Tiankang Anthrax Vaccines Products Offered
12.8.5 Tiankang Recent Development
12.9 叠颈辞驳茅苍别蝉颈蝉-叠补驳辞
12.9.1 叠颈辞驳茅苍别蝉颈蝉-叠补驳辞 Corporation Information
12.9.2 叠颈辞驳茅苍别蝉颈蝉-叠补驳辞 Business Overview
12.9.3 叠颈辞驳茅苍别蝉颈蝉-叠补驳辞 Anthrax Vaccines Sales, Revenue and Gross Margin (2018-2023)
12.9.4 叠颈辞驳茅苍别蝉颈蝉-叠补驳辞 Anthrax Vaccines Products Offered
12.9.5 叠颈辞驳茅苍别蝉颈蝉-叠补驳辞 Recent Development
12.10 CAVAC
12.10.1 CAVAC Corporation Information
12.10.2 CAVAC Business Overview
12.10.3 CAVAC Anthrax Vaccines Sales, Revenue and Gross Margin (2018-2023)
12.10.4 CAVAC Anthrax Vaccines Products Offered
12.10.5 CAVAC Recent Development
12.11 Rosenbusch
12.11.1 Rosenbusch Corporation Information
12.11.2 Rosenbusch Business Overview
12.11.3 Rosenbusch Anthrax Vaccines Sales, Revenue and Gross Margin (2018-2023)
12.11.4 Rosenbusch Anthrax Vaccines Products Offered
12.11.5 Rosenbusch Recent Development
12.12 Agrovet
12.12.1 Agrovet Corporation Information
12.12.2 Agrovet Business Overview
12.12.3 Agrovet Anthrax Vaccines Sales, Revenue and Gross Margin (2018-2023)
12.12.4 Agrovet Anthrax Vaccines Products Offered
12.12.5 Agrovet Recent Development
12.13 Vecol
12.13.1 Vecol Corporation Information
12.13.2 Vecol Business Overview
12.13.3 Vecol Anthrax Vaccines Sales, Revenue and Gross Margin (2018-2023)
12.13.4 Vecol Anthrax Vaccines Products Offered
12.13.5 Vecol Recent Development
12.14 CVCRI
12.14.1 CVCRI Corporation Information
12.14.2 CVCRI Business Overview
12.14.3 CVCRI Anthrax Vaccines Sales, Revenue and Gross Margin (2018-2023)
12.14.4 CVCRI Anthrax Vaccines Products Offered
12.14.5 CVCRI Recent Development
12.15 IVPM
12.15.1 IVPM Corporation Information
12.15.2 IVPM Business Overview
12.15.3 IVPM Anthrax Vaccines Sales, Revenue and Gross Margin (2018-2023)
12.15.4 IVPM Anthrax Vaccines Products Offered
12.15.5 IVPM Recent Development
12.16 Prondil
12.16.1 Prondil Corporation Information
12.16.2 Prondil Business Overview
12.16.3 Prondil Anthrax Vaccines Sales, Revenue and Gross Margin (2018-2023)
12.16.4 Prondil Anthrax Vaccines Products Offered
12.16.5 Prondil Recent Development
12.17 CDV
12.17.1 CDV Corporation Information
12.17.2 CDV Business Overview
12.17.3 CDV Anthrax Vaccines Sales, Revenue and Gross Margin (2018-2023)
12.17.4 CDV Anthrax Vaccines Products Offered
12.17.5 CDV Recent Development
12.18 Indian Immunologicals
12.18.1 Indian Immunologicals Corporation Information
12.18.2 Indian Immunologicals Business Overview
12.18.3 Indian Immunologicals Anthrax Vaccines Sales, Revenue and Gross Margin (2018-2023)
12.18.4 Indian Immunologicals Anthrax Vaccines Products Offered
12.18.5 Indian Immunologicals Recent Development
12.19 Botswana Vaccine Institute
12.19.1 Botswana Vaccine Institute Corporation Information
12.19.2 Botswana Vaccine Institute Business Overview
12.19.3 Botswana Vaccine Institute Anthrax Vaccines Sales, Revenue and Gross Margin (2018-2023)
12.19.4 Botswana Vaccine Institute Anthrax Vaccines Products Offered
12.19.5 Botswana Vaccine Institute Recent Development
12.20 Ceva Sant茅 Animale
12.20.1 Ceva Sant茅 Animale Corporation Information
12.20.2 Ceva Sant茅 Animale Business Overview
12.20.3 Ceva Sant茅 Animale Anthrax Vaccines Sales, Revenue and Gross Margin (2018-2023)
12.20.4 Ceva Sant茅 Animale Anthrax Vaccines Products Offered
12.20.5 Ceva Sant茅 Animale Recent Development
12.21 Intervac
12.21.1 Intervac Corporation Information
12.21.2 Intervac Business Overview
12.21.3 Intervac Anthrax Vaccines Sales, Revenue and Gross Margin (2018-2023)
12.21.4 Intervac Anthrax Vaccines Products Offered
12.21.5 Intervac Recent Development
12.22 JOVAC
12.22.1 JOVAC Corporation Information
12.22.2 JOVAC Business Overview
12.22.3 JOVAC Anthrax Vaccines Sales, Revenue and Gross Margin (2018-2023)
12.22.4 JOVAC Anthrax Vaccines Products Offered
12.22.5 JOVAC Recent Development
13 Anthrax Vaccines Manufacturing Cost Analysis
13.1 Anthrax Vaccines Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Anthrax Vaccines
13.4 Anthrax Vaccines Industrial Chain Analysis
14 麻豆原创ing Channel, Distributors and Customers
14.1 麻豆原创ing Channel
14.2 Anthrax Vaccines Distributors List
14.3 Anthrax Vaccines Customers
15 麻豆原创 Dynamics
15.1 Anthrax Vaccines Industry Trends
15.2 Anthrax Vaccines 麻豆原创 Drivers
15.3 Anthrax Vaccines 麻豆原创 Challenges
15.4 Anthrax Vaccines 麻豆原创 Restraints
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer

Companies Mentioned:

Emergent BioSolutions
Merial
Merck
Zoetis
Bayer Sanidad Animal
Colorado Serum
PharmAthene
Tiankang
叠颈辞驳茅苍别蝉颈蝉-叠补驳辞
CAVAC
Rosenbusch
Agrovet
Vecol
CVCRI
IVPM
Prondil
CDV
Indian Immunologicals
Botswana Vaccine Institute
Ceva Sant茅 Animale
Intervac
JOVAC

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.